# China Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore China HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: China (CHN) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $16.8B - Products: 49 - Buyer markets: 38 - Average CAGR: +21.8% - Global sector size: $787.3B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $296.0B | $5.3B | $105.2B | +17.0% | 21 | +0.8% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $162.1B | $430.1M | $66.5B | +16.7% | 18 | +0.3% | | HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $29.2B | $203.6M | $46.4B | +21.7% | 5 | +0.4% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $35.3B | $288.0M | $36.3B | +54.9% | 7 | +0.6% | | HS 300220 - Vaccines: for human medicine | $29.2B | $537.3K | $24.3B | +3.5% | 8 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $1.6B | $20.0B | +21.1% | 3 | +7.3% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $28.0B | $24.1M | $16.1B | +7.6% | 6 | +0.1% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $23.0B | $340.1M | $13.2B | +26.7% | 7 | +2.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $15.2B | $661.9M | $12.1B | +46.5% | 6 | +2.5% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $3.9B | $11.0B | +24.6% | 3 | +18.1% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $29.6M | $10.7B | +12.1% | 3 | +0.3% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $6.1B | $135.9M | $8.1B | +9.3% | 2 | +1.6% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $976.8M | $7.3B | +15.7% | 3 | +7.6% | | HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $2.3K | $6.7B | -7.7% | 1 | +0.0% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $4.6B | $56.2M | $6.5B | +8.5% | 3 | +1.2% | | HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $3.3B | $2.3M | $6.3B | +44.6% | 2 | +0.1% | | HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $164.6M | $5.9B | +14.8% | 3 | +3.0% | | HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $6.8B | $196.2K | $5.0B | +10.0% | 2 | +0.0% | | HS 281820 - Aluminium oxide: other than artificial corundum | $4.6B | $7.5M | $4.3B | +14.3% | 3 | +0.1% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $3.0B | $66.5M | $4.2B | +50.1% | 2 | +2.3% | | HS 330300 - Perfumes and toilet waters | $6.6B | $72.6M | $4.0B | +38.0% | 2 | +1.0% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $3.4B | $1.8M | $4.0B | -28.2% | 2 | +2.9% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $2.6M | $3.8B | +43.2% | 2 | +0.0% | | HS 290110 - Acyclic hydrocarbons: saturated | $2.0B | $5.0M | $3.4B | +24.0% | 3 | +0.2% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $8.5B | $401.6M | $3.4B | +14.7% | 3 | +3.8% | | HS 282200 - Cobalt oxides and hydroxides: commercial cobalt oxides | $1.6B | $95.2K | $3.1B | +8.3% | 1 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $10.4B | $585.8M | $2.9B | +31.1% | 2 | +5.2% | | HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $3.9B | $246.8M | $2.5B | +33.6% | 2 | +4.6% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $79.8M | $2.1B | +34.2% | 2 | +2.2% | | HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $495.8K | $1.9B | +28.3% | 1 | +0.0% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $1.9B | $133.6M | $1.9B | +91.6% | 1 | +7.1% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $194.6M | $1.8B | +18.4% | 1 | +5.1% | | HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $167.8M | $1.7B | +15.2% | 1 | +7.1% | | HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $3.5M | $1.7B | +29.9% | 1 | +0.4% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.0B | $380.4M | $1.5B | +18.0% | 1 | +12.8% | | HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $287.7K | $1.5B | +24.3% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $114.4K | $1.4B | +14.0% | 1 | +0.0% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $7.1M | $1.4B | +21.1% | 1 | +0.6% | | HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $1.8M | $1.3B | +11.6% | 1 | +0.1% | | HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $4.9B | $323.2M | $1.3B | +23.2% | 1 | +6.6% | | HS 284330 - Gold compounds | $877.8M | $20.3K | $1.2B | +17.2% | 1 | +0.0% | | HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $11.6M | $1.2B | +35.8% | 1 | +1.8% | | HS 310559 - Fertilizers, mineral or chemical: containing the two fertilizing elements nitrogen and phosphorus, other than nitrates and phosphates | $581.7M | $105.8K | $1.1B | +58.9% | 1 | +0.0% | | HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $1.7M | $1.1B | +11.1% | 1 | +0.3% | | HS 290250 - Cyclic hydrocarbons: styrene | $768.8M | $111.9K | $1.1B | +47.3% | 1 | +0.0% | | HS 293410 - Heterocyclic compounds: containing an unfused thiazole ring (whether or not hydrogenated) in the structure | $890.3M | $943.5K | $1.1B | +19.0% | 1 | +0.1% | | HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $979.7M | $15.0M | $1.0B | +12.9% | 1 | +1.5% | | HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $669.2M | $6.2M | $1.0B | +20.0% | 1 | +0.9% | | HS 310210 - Fertilizers, mineral or chemical: nitrogenous, urea, whether or not in aqueous solution | $2.0B | $12.1M | $1.0B | +11.7% | 1 | +0.6% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $144.2B calculated opportunity across 24 products. - Germany (DEU): $41.6B calculated opportunity across 14 products. - Slovenia (SVN): $39.2B calculated opportunity across 7 products. - Switzerland, Liechtenstein (CHE): $37.7B calculated opportunity across 5 products. - Belgium (BEL): $31.5B calculated opportunity across 7 products. - Italy (ITA): $21.2B calculated opportunity across 5 products. - Netherlands (NLD): $19.3B calculated opportunity across 6 products. - Canada (CAN): $15.0B calculated opportunity across 9 products. - Mexico (MEX): $12.7B calculated opportunity across 7 products. - Spain (ESP): $11.3B calculated opportunity across 6 products. - Japan (JPN): $10.7B calculated opportunity across 4 products. - France (FRA): $10.1B calculated opportunity across 5 products. ## Growth stars - HS 382499: +91.6% average CAGR, $1.9B calculated opportunity. - HS 310559: +58.9% average CAGR, $1.1B calculated opportunity. - HS 300214: +54.9% average CAGR, $36.3B calculated opportunity. - HS 290919: +50.1% average CAGR, $4.2B calculated opportunity. - HS 290250: +47.3% average CAGR, $1.1B calculated opportunity. - HS 382600: +46.5% average CAGR, $12.1B calculated opportunity. - HS 293319: +44.6% average CAGR, $6.3B calculated opportunity. - HS 381512: +43.2% average CAGR, $3.8B calculated opportunity. - HS 330300: +38.0% average CAGR, $4.0B calculated opportunity. - HS 293339: +35.8% average CAGR, $1.2B calculated opportunity. ## Diversification opportunities - HS 300490: 21 buyer markets, $105.2B calculated opportunity. - HS 300215: 18 buyer markets, $66.5B calculated opportunity. - HS 300220: 8 buyer markets, $24.3B calculated opportunity. - HS 300214: 7 buyer markets, $36.3B calculated opportunity. - HS 300439: 7 buyer markets, $13.2B calculated opportunity. - HS 300212: 6 buyer markets, $16.1B calculated opportunity. - HS 382600: 6 buyer markets, $12.1B calculated opportunity. - HS 293719: 5 buyer markets, $46.4B calculated opportunity. - HS 293359: 3 buyer markets, $20.0B calculated opportunity. - HS 293399: 3 buyer markets, $11.0B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.